NewSelf: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.newself.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “NewSelf” on the pictured label, suggesting NewSelf is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Same active ingredient as Ozempic® & Wegovy®” “Same active ingredient as Mounjaro® & Zepbound®” “What is the FDA-approved use of Wegovy?” “What is the FDA-approved use of Zepbound?””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

newself.com returned a live storefront on 2026-08-09, titled "NewSelf Weight Loss Protocol", with a published price ladder and a working cart, so the site was transacting at that check.

The two FAQ questions are the interesting part, because on their face they are the responsible thing to do. "What is the FDA-approved use of Wegovy?" is a true question about a real approved drug, and answering it accurately is a service. FDA's point is about placement, not accuracy: put that question on a page selling a compounded product and the approval it describes drifts across to the thing being sold, without anyone having claimed it. That is a hard defect to shop around, because it does not live in any one sentence you could fact-check — it lives in what a page is about versus what it discusses. When you are weighing this seller's price against another's, the honest read is that nothing here says the medicine is bad or the price is wrong; it says the FDA-approval language surrounding the offer belongs to a different product than the one in the cart.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence NewSelf failed to respond.